Fosinopril sodium (CAS 88889-14-9)
QUICK LINKS
Fosinopril sodium is an ACE(angiotensin-converting enzyme) inhibitor. Introducing Fosinopril sodium, a newly developed synthetic compound designed for scientific research purposes. This compound, known for its high selectivity as a cyclooxygenase-2 (COX-2) inhibitor, holds immense potential across various scientific research applications. By effectively inhibiting COX-2, Fosinopril sodium plays a role in hindering the production of prostaglandins—molecules associated with inflammation and pain. Through this inhibition, Fosinopril sodium showcases its ability to alleviate both inflammation and pain, as demonstrated in animal models. Moreover, its efficacy extends to impeding the proliferation of cancer cells in animal models. Notably, Fosinopril sodium has also exhibited effectiveness in reducing the levels of specific inflammatory mediators, including prostaglandins, as observed in cell culture experiments.
Fosinopril sodium (CAS 88889-14-9) References
- A new treatment forInterdialytic hyperkalemia - the use of fosinopril sodium. | Mousa, D., et al. 1999. Am J Nephrol. 19: 395-9. PMID: 10393377
- Protection of organic trauma in sinoaortic-denervated rats treated with fosinopril. | Tao, X. and Liu, GL. 2003. Yao Xue Xue Bao. 38: 743-7. PMID: 14730896
- Microemulsion liquid chromatographic method for characterisation of fosinopril sodium and fosinoprilat separation with chemometrical support. | Janci, B., et al. 2005. Anal Bioanal Chem. 383: 687-94. PMID: 16195875
- Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects. | Duchin, KL., et al. 1991. J Clin Pharmacol. 31: 58-64. PMID: 1646240
- Fosinopril H(2)-receptor antagonists interaction studies by derivative spectroscopy. | Sultana, N., et al. 2007. Pak J Pharm Sci. 20: 19-25. PMID: 17337423
- Monitoring of fosinopril sodium impurities by liquid chromatography-mass spectrometry including the neural networks in method evaluation. | Jancić, B., et al. 2008. J Chromatogr A. 1189: 366-73. PMID: 18154978
- Relative contribution of the gut, liver, and lung to the first-pass hydrolysis (bioactivation) of orally administered 14C-fosinopril sodium in dogs. In vivo and in vitro studies. | Morrison, RA., et al. 1990. Drug Metab Dispos. 18: 253-7. PMID: 1971582
- [Protective effect of fosinopril sodium pretreatment combined with ischemic postconditioning on rat heart underwent myocardial ischemia/reperfusion injury]. | Zhang, DW., et al. 2010. Zhonghua Xin Xue Guan Bing Za Zhi. 38: 633-7. PMID: 21055289
- The effect of fosinopril sodium on cerebral blood flow in moderate essential hypertension. | Waldemar, G., et al. 1990. Am J Hypertens. 3: 464-70. PMID: 2142429
- Disposition of fosinopril sodium in healthy subjects. | Singhvi, SM., et al. 1988. Br J Clin Pharmacol. 25: 9-15. PMID: 2967089
- Aggregation behavior of fosinopril sodium--a new angiotensin-converting enzyme inhibitor. | Wang, Z., et al. 1995. J Pharm Sci. 84: 609-13. PMID: 7658352
- Quantitative analysis of fosinopril sodium by capillary zone electrophoresis and liquid chromatography. | Lozano, R., et al. 1995. J Pharm Biomed Anal. 13: 139-48. PMID: 7766720
- A lamellar liquid crystal with fosinopril sodium. | Friberg, SE., et al. 1994. J Pharm Sci. 83: 677-9. PMID: 8071820
- Solid-state NMR and IR for the analysis of pharmaceutical solids: polymorphs of fosinopril sodium. | Brittain, HG., et al. 1993. J Pharm Biomed Anal. 11: 1063-9. PMID: 8123714
- Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein(a) by fosinopril. | Schlueter, W., et al. 1993. Am J Cardiol. 72: 37H-44H. PMID: 8285181
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Fosinopril sodium, 25 mg | sc-205702 | 25 mg | $160.00 | |||
Fosinopril sodium, 100 mg | sc-205702A | 100 mg | $518.00 |